menu
    • menu

    Company profile for Inke S.A

    Inke SA-PSE
    News
    Micronization Enhances Bioavailability in Dry Powder Inhalers

    17 Mar 2026

    // PRESS RELEASE

    APIs for Asthma and COPD: Challenges in Inhalation Formulations

    05 Mar 2026

    // PRESS RELEASE

    Regulatory Pathways for Inhalable APIs in the EU and US

    23 Feb 2026

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Inke RM

    Contact Supplier

    Website

    CPhI China

    Attending

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    https://www.youtube.com/embed/m-45ySbXUKc?si=ix6_VzdEAx7ufTj2

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    Key Products KEY PRODUCTS

    SERVICES

    Key Products KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Inke S.A: APIs manufacturing plant.

    Related CompaniesRelated Companies

    About

    Inke S.A., is focused since 1980 in the development and manufacture of the highest quality Active Pharmaceutical Ingredients (APIs) with complex synthesis processes for diverse therapeutic areas, but mainly for use in Respiratory. Inke has been successfully inspected by every major global authority for a wide array of products (last inspection on behalf of US-FDA was in 2023). For the last two decades, the company has made strong strides to become a prestige provider of respiratory APIs for inhalation. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Inke S.ASpain_new Flag
    Country
    Country
    Spain
    Address
    Address
    Area Industrial Llobregat, Argent,1 08755 Castellbisbal Barcelona
    Telephone
    Telephone
    +34 936828180
    Client Email
    Email
    contact-inke@inke.es
    Client Website
    Website
    https://www.inke.es/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/inke/
    youtube
    YouTube
    http://www.youtube.com/@InkePharma
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI China

    Attending

    envelop Contact Supplier

    CPhI China

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    INTERVIEW #SpeakPharma

    read-more
    read-more
    “Due to its 20-year mastery in micronization, Inke has emerged a cornerstone in treating global respiratory diseases”

    mic“Due to its 20-year mastery in micronization, Inke has emerged a cornerstone in treating global respiratory diseases”

    This week, SpeakPharma interviews Miquel Bachs, CEO of Inke, a company with over two decades of expertise in micronization and particle engineering, and a leader in providing high-quality, effective solutions in the global fight against chronic respiratory diseases such as COPD and asthma. In this insightful conversation, Bachs shares Inke’s strategic vision, technological innovations, and commitment to sustainability, offering a comprehensive look at how the company is shaping the future of respiratory health. HIGHLIGHTS// Inke’s strategic vision/ technological innovations/ commitment to sustainability Studies suggest that 13 percent of people over 40 years of age, the world over, have chronic obstructive pulmonary disease (COPD). Given the increasing prevalence of respiratory diseases, how does Inke position itself as a leader in the development and manufacturing of respiratory APIs? Inke has established itself as a global leader in generic respiratory API development through our unique blend  of technological innovation, expertise in micronization, and a comprehensive portfolio of inhalation therapies. With over 20 years of experience in micronization and particle engineering, our ability to customize APIs to meet specific client requirements has resulted in highly effective, high-quality products tailored for respiratory therapies. The increasing prevalence of chronic respiratory diseases, such as COPD and asthma, has only underscored Inke’s pivotal role in supporting the pharmaceutical industry’s need for advanced treatments. We specialize in bronchodilators and other critical respiratory APIs that improve patient outcomes and meet the stringent regulatory requirements of global health authorities. Our end-to-end approach, from early-stage API development to commercial-scale production, ensures that we maintain the highest standards of quality, safety, and efficacy. As the market for respiratory APIs continues to evolve, Inke remains committed to expanding its portfolio to address unmet therapeutic needs. Beyond respiratory APIs, we are also prioritizing growth in CNS treatments and building on our expertise in complex molecule synthesis. This strategic focus allows us to provide an integrated solution that not only meets current market demands but also anticipates future pharmaceutical trends. HIGHLIGHTS// comprehensive portfolio of inhalation therapies/ over 20 years of experience in micronization and particle engineering/ specialize in bronchodilators and other critical respiratory APIs/ prioritizing growth in CNS treatments In the field of micronization, what differentiates Inke’s approach from that of other manufacturers of respiratory APIs? What sets Inke apart in micronization is our advanced particle size reduction technology and our dedication to precision. Our facility is equipped with various milling techniques such as Cone, Jet, and Pin mills, allowing us to reduce particle size while stabilizing the amorphous content to ensure consistent quality. Our in-depth understanding of respiratory APIs, combined with our ability to tailor solutions for each customer, results in APIs with improved solubility, stability, and bioavailability, which are critical for the efficacy of inhalation products. This, along with our exceptional quality standards and a flawless audit track record, has positioned us as a key partner for major players in the inhalation market. HIGHLIGHTS// advanced particle size reduction technology/ technological innovations/ tailor solutions/ improved solubility, stability, and bioavailability Developing complex APIs can be challenging. How does Inke ensure a smooth and successful partnership throughout the development and manufacturing process, including customization, ensuring regulatory compliance and timely delivery? At Inke, we are dedicated to fostering strong partnerships with our clients through a collaborative approach that prioritizes open communication and mutual understanding. Our commitment to quality and personalized service sets us apart in the pharmaceutical landscape. Our team takes the time to engage in comprehensive discussions to customize our solutions, ensuring alignment with client specifications across all batches and grades. This commitment to flexibility allows us to respond effectively to evolving requirements, solidifying Inke’s reputation as a reliable partner. We understand that navigating regulatory landscapes can be challenging. That's why our team is equipped to manage all aspects of the regulatory process with meticulous attention to detail. From the submission of Drug Master Files (DMFs) and Certificates of Suitability to crafting precise responses to potential Deficiency Letters, we ensure compliance at every step. Moreover, we offer extensive support in patent and intellectual property matters, providing technical assistance and guidance tailored to the specific requirements of each region. Our unwavering dedication to quality, coupled with our agile response capabilities, enables us to deliver exceptional results while maintaining transparency and trust. At Inke, we are committed to building lasting relationships that drive success for both our clients and our organization. HIGHLIGHTS// ensuring alignment with client specifications/ manage all aspects of the regulatory process/ support in patent and intellectual property matters Given Inke’s global presence, what are the key markets for growth and how does Inke plan to expand its market reach and strengthen its position in these regions? Inke is strategically focused on expanding its footprint in the European and US markets, where we continue to prioritize our efforts. The US market remains pivotal for us, especially considering our successful FDA inspections and ongoing regulatory compliance efforts that solidify our reputation. Japan is another significant market where we have established a robust presence, reflecting our commitment to high-quality manufacturing and innovation. Looking ahead, China represents a key growth opportunity for Inke. With 12 active DMFs registered, we are well-positioned to tap into this burgeoning market. Our strategy involves leveraging our existing capabilities to navigate regulatory landscapes and fostering strong partnerships within the region, thereby enhancing our market reach and influence in the pharmaceutical sector. HIGHLIGHTS// expanding footprint in the European and US markets/ China represents a key growth opportunity for Inke With Inke expanding into contract manufacturing organization (CMO) services, how does this new offering align with Inke’s broader strategic goals, and what advantages does it provide to pharmaceutical partners? At Inke, the introduction of CMO services is a natural extension of our core expertise in the development and manufacturing of high-quality generic APIs. Our expansion into CMO is part of a strategic move to diversify our service portfolio, allowing us to offer end-to-end solutions for our clients. The CMO service integrates seamlessly with our expertise in API manufacturing, particularly in micronization, which has been a key differentiator for Inke for over two decades. With our advanced particle engineering capabilities, we can offer tailored solutions that meet specific technical and regulatory requirements. Whether it is small-batch production or scaling up to commercial quantities, we offer the flexibility to accommodate a wide range of customer needs. This adaptability, paired with our deep expertise in micronization, allows us to support evolving project needs, maintaining the highest standards of consistency, quality, and performance that define Inke’s footprint. HIGHLIGHTS// CMO is part of a strategic move to diversify our service portfolio/ deep expertise in micronization What is Inke’s commitment to sustainability and corporate social responsibility and how is it integrating sustainable practices into its operations and product development? At Inke, we recognize that integrating environmental, social, and governance (ESG) principles into our operations is not just a responsibility but a pathway to long-term success. Our ESG vision is centered around aligning business growth with sustainable practices that positively impact our communities and the environment. We are dedicated to environmental responsibility, actively implementing initiatives such as efficient wastewater treatment and water reuse systems to minimize our ecological footprint. Our recent investments in energy efficiency include the installation of a 135 kWp solar panel system, which underscores our commitment to reducing emissions and resource consumption across our manufacturing and research facilities. Inke is also committed to fostering a diverse and inclusive workforce. With a notable increase in our team members, particularly in operations and quality assurance, we prioritize career development and the well-being of our employees. By adhering to high regulatory standards, we ensure our products meet stringent global requirements, enhancing our transparency and compliance. Through these initiatives, Inke aims to cultivate sustainable practices that not only support our business objectives but also contribute positively to the pharmaceutical industry and society at large. HIGHLIGHTS// integrating ESG principles/ efficient wastewater treatment and water reuse systems/ installation of a 135 kWp solar panel system/ diverse and inclusive workforce

    Impressions: 2605

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/due-to-its-20-year-mastery-in-micronization-inke-has-emerged-a-cornerstone-in-treating-global-respiratory-diseases

    #SpeakPharma With Inke
    28 Oct 2024
    Share info Share

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2026

    read-more

      https://www.pharmacompass.com/pdf/party/content/inke-sa-party-content-65800.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/inke-sa-party-content-99309.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Ophthalmic API Product List 2026

    read-more

      https://www.pharmacompass.com/pdf/party/content/inke-sa-party-content-31223.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Inke Completes Pharmanoid Acquisition

    read-more

      https://www.pharmacompass.com/pdf/party/content/inke-sa-party-content-44270.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    API Product List 2026

    read-more

      https://www.pharmacompass.com/pdf/party/content/inke-sa-party-content-10169.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    API Under Development 2026

    read-more

      https://www.pharmacompass.com/pdf/party/content/inke-sa-party-content-28636.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    CNS API Product List 2026

    read-more

      https://www.pharmacompass.com/pdf/party/content/inke-sa-party-content-56766.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Inhalation API Product List 2026

    read-more

      https://www.pharmacompass.com/pdf/party/content/inke-sa-party-content-40027.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2026

    read-more

      https://www.pharmacompass.com/pdf/party/content/inke-sa-party-content-87458.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    Prostaglandin market to cross US$ 1.27 bn by 2035; Liquidia’s Yutrepia okayed for pulmonary hypertension

    Prostaglandin market to cross US$ 1.27 bn by 2035; Liquidia’s Yutrepia okayed for pulmonary hypertension

    Prostaglandins are natural fatty acid compounds produced by the human body. They are made from a type of fat known as arachidonic acid and act like messengers, controlling many functions such as inflammation, blood flow, muscle contraction, and fluid drainage in the eye. Prostaglandin APIs are synthetic (lab-made) versions of natural prostaglandins that are used to create medicines. Prostaglandin-based medicines are used in obstetrics and gynecology, gastroenterology, urology, and cosmetics, and their use is also being explored in certain cardiovascular and respiratory conditions. One of the largest and most important uses of prostaglandin APIs is in ophthalmology (eye care), where they are used as first-line therapy for open-angle glaucoma (a chronic, progressive eye disease) and ocular hypertension (a condition where pressure inside the eye is consistently higher than normal). In ophthalmic applications, these drugs usually serve as prodrugs – inactive in the formulation but converted into their active form after entering the eye.According to estimates, the global prostaglandin market is valued at US$ 0.63 billion in 2025 and is poised to grow from US$ 0.68 billion in 2026 to US$ 1.27 billion by 2035, growing at a CAGR of 7.1 percent between 2026 and 2035.Prostaglandin API manufacturing is a highly specialised field, with only a few experienced manufacturers. Companies such as EUROAPI, Cayman Pharma, Chirogate International, Kyowa Pharma Chemical, Everlight Chemical, and Yonsung Fine Chemicals are key players with strong capabilities in complex chemistry.FDA allows Glaukos’ iDose TR to be re-administered for treating eye diseases; approves Liquidia’s Yutrepia The prostaglandin market continues to see steady regulatory activity and innovations. In ophthalmology, Glaukos Corporation’s iDose TR received a labelling supplement from the US Food and Drug Administration (FDA) that allows for re-administration of the medication indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). The intracameral implant was originally approved in December 2023 for single use. This update was supported by long-term safety data demonstrating good tolerability in patients with OAG and OHT. Similarly, Santen Pharmaceutical secured manufacturing and marketing approval in Japan for Setaneo (sepetaprost) ophthalmic solution 0.002% in August 2025 for the treatment of glaucoma and OHT. In April 2025, Santen also received approval in China for Tapcom (tafluprost + timolol maleate), a preservative-free fixed-dose combination therapy that lowers intraocular pressure (IOP) in patients with OAG and OHT.Beyond ophthalmology, prostaglandin APIs are also driving advancements in respiratory care. Liquidia Corporation received FDA approval in May 2025 for Yutrepia (treprostinil) inhalation powder for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). While PAH is a serious and progressive disease where blood pressure in the lung arteries rises, causing them to narrow and harden, PH-ILD is a serious complication in which high blood pressure develops in the lung arteries due to lung scarring. Yutrepia is the first and only prostacyclin dry-powder formulation enabled by Liquidia’s proprietary technology.  Access the Interactive Dashboard on Prostaglandin Developments (Free Excel Available)Nicox’s drug scores phase 3 win in glaucoma, OHT; United seeks expanded approval for Tyvaso to treat pulmonary fibrosisInnovation in prostaglandins is increasingly focused on enhanced efficacy and sustained drug delivery. French ophthalmology company Nicox has reported positive phase 3 results for its ophthalmic solution NCX 470, demonstrating consistent lowering of intraocular pressure in OAG and OHT. Nicox is likely to submit a new drug application for NCX 470 sometime soon, with a potential approval and launch expected in 2027.Meanwhile, US-based SpyGlass Pharma is advancing sustained-release innovation through intraocular lens (IOL)-based and ring-based drug delivery systems. Its Bimatoprost Drug Pad–Intraocular Lens (BIM-IOL) system (currently in phase 3 trials) integrates drug delivery with cataract surgery to enable sustained therapy for up to three years. The company is also developing a preclinical Bimatoprost Drug Ring System (BIM-DRS) designed for similarly extended drug release. In respiratory indications, Insmedis progressing treprostinil palmitil inhalation powder through phase 3 trials for PH-ILD, as well as for idiopathic pulmonary fibrosis and PAH.Additionally, United Therapeutics is expanding the clinical scope of Tyvaso DPI (treprostinil). Following its global approval in 2022 for PAH, the therapy is now under regulatory review in the US and Canada for progressive pulmonary fibrosis and idiopathic pulmonary fibrosis.  Access the Interactive Dashboard on Prostaglandin Developments (Free Excel Available)Glaukos sets up new R&D facility in Alabama, Inke acquires Pharmanoid to strengthen presence in prostaglandins Several players are expanding capacities due to rising demand across ophthalmology. Glaukos Corporation is setting up a new research, development, and manufacturing facility in Huntsville, Alabama. The planned 200,000 square-foot site, to be built on a 25-acre campus in Cummings Research Park, envisages an investment of over US$ 80 million. Expected to be completed by 2030, the facility is designed to augment the company’s existing infrastructure and support long-term growth, particularly in ophthalmic therapies including sustained-release drug delivery systems.EUROAPIis undertaking a significant capacity expansion at its Budapest site. The company has committed €50 million (US$ 54.8 million) to install a new state-of-the-art production plant focused on prostaglandins. The project aims to debottleneck existing operations and introduce new multi-purpose manufacturing equipment, ultimately more than doubling the site’s prostaglandin production capacity by 2027. The expansion will also strengthen EUROAPI’s highly potent API (HPAPI) capabilities.Alongside capacity additions by established players, the market is also witnessing consolidation and capability expansion through acquisitions. For instance, Essential Pharma acquired Ventavis (iloprost trometamol) from Bayer AG, including rights to the accompanying Breelib nebuliser delivery technology. Ventavis, a prostacyclin analogue, is a well-established treatment for adult patients with primary pulmonary hypertension.Inke strengthened its presence in ophthalmology-focused high-potency APIs (HPAPIs), including prostaglandins, through the acquisition of Pharmanoid in December 2025. Backed by regulatory approvals across 25+ countries, Pharmanoid enhances Inke’s capabilities in complex API production and supports its ambition to build a leading European platform for advanced API development and manufacturing. The Barcelona facility is capable of producing and handling APIs across all potency levels while adhering to SafeBridge Scale OEB4 (Occupational Exposure Band 4) containment protocols, a classification for high-potency substances requiring strict controls to limit occupational exposure.With more than two decades of experience, Inke is recognized for innovating and manufacturing high-quality APIs, delivering expertise, safety, and excellence across inhalation, CNS, and ophthalmic therapies, while supporting pharmaceutical companies worldwide. The ophthalmic API commercial portfolio includes bimatoprost, latanoprost, tafluprost, and travoprost, while the next-generation prostaglandin analog pipeline includes bimatoprost grenod and latanoprostene bunod.  Access the Interactive Dashboard on Prostaglandin Developments (Free Excel Available)Our viewInnovation is guiding the prostaglandins market towards long-acting, sustained-release formulations and novel delivery systems. These innovations are driving steady growth in prostaglandins, while capacity expansions are strengthening capabilities in complex and highly potent APIs. Overall, this remains a niche but important market to watch. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 617

    https://www.pharmacompass.com/radio-compass-blog/prostaglandin-market-to-cross-us-1-27-bn-by-2035-liquidia-s-yutrepia-okayed-for-pulmonary-hypertension

    #PharmaFlow by PHARMACOMPASS
    14 May 2026
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Micronization Enhances Bioavailability in Dry Powder Inhalers
    Micronization Enhances Bioavailability in Dry Powder Inhalers

    17 Mar 2026

    // PRESS RELEASE

    https://www.inke.es/news/how-micronization-enhances-bioavailability-in-dpis/

    PRESS RELEASE
    17 Mar 2026
    Share Share
    APIs for Asthma and COPD: Challenges in Inhalation Formulations
    APIs for Asthma and COPD: Challenges in Inhalation Formulations

    05 Mar 2026

    // PRESS RELEASE

    https://www.inke.es/news/apis-for-asthma-and-copd-challenges/

    PRESS RELEASE
    05 Mar 2026
    Share Share
    Regulatory Pathways for Inhalable APIs in the EU and US
    Regulatory Pathways for Inhalable APIs in the EU and US

    23 Feb 2026

    // PRESS RELEASE

    https://www.inke.es/news/regulatory-pathways-for-inhalable-apis-eu-us/

    PRESS RELEASE
    23 Feb 2026
    Share Share
    Upcoming Trends in Inhalation Drug Delivery Technologies
    Upcoming Trends in Inhalation Drug Delivery Technologies

    12 Feb 2026

    // PRESS RELEASE

    https://www.inke.es/news/upcoming-trends-in-inhalation-drug-delivery/

    PRESS RELEASE
    12 Feb 2026
    Share Share
    Advanced Particle Engineering for Reliable& High-Performance APIs
    Advanced Particle Engineering for Reliable& High-Performance APIs

    29 Jan 2026

    // PRESS RELEASE

    https://www.inke.es/news/science-behind-particle-engineering-for-inhalation-therapies/

    PRESS RELEASE
    29 Jan 2026
    Share Share
    How to Select a Strategic API Partner High-Quality Manufacturer
    How to Select a Strategic API Partner High-Quality Manufacturer

    14 Jan 2026

    // PRESS RELEASE

    https://www.inke.es/news/choosing-the-right-api-supplier-5-critical-criteria/

    PRESS RELEASE
    14 Jan 2026
    Share Share

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Services

    Discover the service capabilities from this company

    API Manufacturing

    Discover their expertise for : API Manufacturing

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    KEY SERVICES

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Inke S.A VB Popup full-view
    Aseptic Micronization
    full-view

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Contact Inke S.A and get a quotation

    Inke S.A is a supplier offers 51 products (APIs, Excipients or Intermediates).

    Find Formoterol Fumarate bulk with DMF, CEP, JDMF offered by Inke S.A

    Find Granisetron Hydrochloride bulk with DMF, CEP, JDMF offered by Inke S.A

    Find Aprepitant bulk with DMF, CEP offered by Inke S.A

    Find Glycopyrronium Bromide bulk with DMF, CEP offered by Inke S.A

    Find Ondansetron Hydrochloride bulk with DMF, CEP offered by Inke S.A

    Find Risperidone bulk with DMF, CEP offered by Inke S.A

    Find Salmeterol Xinafoate bulk with DMF, CEP offered by Inke S.A

    Find Tiotropium Bromide bulk with DMF, CEP offered by Inke S.A

    Find Aclidinium Bromide bulk with DMF offered by Inke S.A

    Find Arformoterol Tartrate bulk with DMF offered by Inke S.A

    Find Carvedilol bulk with JDMF offered by Inke S.A

    Find Clevidipine bulk with DMF offered by Inke S.A

    Find Eletriptan Hydrobromide bulk with JDMF offered by Inke S.A

    Find Enalapril Maleate bulk with CEP offered by Inke S.A

    Find Granisetron bulk with DMF offered by Inke S.A

    Find Indacaterol Maleate bulk with DMF offered by Inke S.A

    Find Latanoprost bulk with DMF offered by Inke S.A

    Find Loratadine bulk with JDMF offered by Inke S.A

    Find Montelukast Sodium bulk with JDMF offered by Inke S.A

    Find Olanzapine bulk with DMF offered by Inke S.A

    Find Olodaterol Hydrochloride bulk with DMF offered by Inke S.A

    Find Ondansetron bulk with DMF offered by Inke S.A

    Find Quetiapine Hemifumarate bulk with JDMF offered by Inke S.A

    Find Revefenacin bulk with DMF offered by Inke S.A

    Find Tetrabenazine bulk with DMF offered by Inke S.A

    Find Travoprost bulk with DMF offered by Inke S.A

    Find Umeclidinium Bromide bulk with DMF offered by Inke S.A

    Find Vilanterol Trifenatate bulk with DMF offered by Inke S.A

    Find Zolmitriptan bulk with DMF offered by Inke S.A

    Find Asenapine Maleate bulk offered by Inke S.A

    Find Bimatoprost bulk offered by Inke S.A

    Find Bimatoprost Grenod bulk offered by Inke S.A

    Find Daprodustat bulk offered by Inke S.A

    Find Daridorexant bulk offered by Inke S.A

    Find Ensifentrine bulk offered by Inke S.A

    Find Glycopyrronium Tosylate bulk offered by Inke S.A

    Find Granisetron Hydrochloride bulk offered by Inke S.A

    Find Imidapril Hydrochloride bulk offered by Inke S.A

    Find Indacaterol Acetate bulk offered by Inke S.A

    Find Latanoprostene Bunod bulk offered by Inke S.A

    Find Mavacamten bulk offered by Inke S.A

    Find Otilonium Bromide bulk offered by Inke S.A

    Find Prasugrel bulk offered by Inke S.A

    Find Prasugrel Hydrochloride bulk offered by Inke S.A

    Find Rivaroxaban bulk offered by Inke S.A

    Find Roflumilast bulk offered by Inke S.A

    Find Rotigotine bulk offered by Inke S.A

    Find Solriamfetol Hydrochloride bulk offered by Inke S.A

    Find Tafamidis bulk offered by Inke S.A

    Find Tafamidis Meglumine bulk offered by Inke S.A

    Find Tafluprost bulk offered by Inke S.A

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search